胜任细胞市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球胜任细胞市场预计将从 2025 年的 21.5 亿美元成长到 2031 年的 38.8 亿美元，年复合成长率为 10.34%。

这个市场主要由经过物理或化学改造以接受外源遗传物质的细菌细胞组成，这些细菌细胞是重组蛋白质表现和分子克隆的关键工具。该领域的成长主要受生物治疗药物需求不断增长以及基因工程在工业界和学术界应用日益广泛所驱动。此外，药物研发管线中强有力的研发倡议也推动了这一成长，这些试剂对于文库建构和DNA扩增至关重要。根据国际药品製造商和公司联合会（IFPMA）的数据，到2024年，全球药物研发管线将包含超过12,700种处于不同研发阶段的药物。

儘管成长前景强劲，但市场仍面临维持细胞活性所需的严格低温运输物流的重大挑战。胜任细胞对温度变化极为敏感，在处理和运输过程中需要持续的超低温储存。任何环境条件的波动都可能显着降低转换效率，导致实验失败，并增加商业和研究实验室的营运成本。

市场驱动因素

全球胜任细胞市场的主要驱动力是生物製药和重组蛋白生产需求的不断增长。随着生物製药公司将重心从小分子药物转向重组疫苗和单株抗体等大分子疗法，它们越来越依赖高效的胜任细胞进行蛋白质表现和质体克隆。这些细胞是扩增下游生物製药生产所需遗传物质的关键组成部分，其应用对药物研发的成功至关重要。这一成长动能十分明显，根据美国食品药物管理局（FDA）统计，2023年有55种新型疗法核准，截至2024年1月，已有17种新型生物製品核准。

生命科学研究领域私人和政府投资的不断增加进一步推动了市场成长。这些投资为先进的工作流程和试剂采购提供了必要的资金。良好的资本环境使商业和学术实验室能够确保高品质胜任细胞的稳定供应，这对于缩短计划週期和最大限度地减少实验误差至关重要。例如，根据仲量联行 (JLL) 2024 年 9 月发布的报告，美国生命科学领域的创业投资在今年上半年成长了 34%，预示着研发领域将迎来新的资金流入。此外，公共政策也支持这一趋势。 2024 年 10 月，英国政府设立了 5.2 亿英镑的生命科学创新製造基金，旨在加强英国国内关键诊断试剂和药品的生产能力。

市场挑战

严格的低温运输物流需求是全球胜任细胞市场扩张的一大障碍。胜任细胞对温度波动高度敏感，需要超低温储存才能维持转化效率。这种脆弱性使得运输必须采用液态氮或干冰等特殊且昂贵的运输通讯协定。这些复杂的物流要求构成了市场准入和成长的巨大障碍，因为即使运输过程中温度出现轻微波动，也可能导致细胞完全丧失活性，迫使研究人员放弃实验并遭受重大经济损失。

这些营运风险会直接阻碍市场扩充性，对商业和研究实验室的预算带来压力。处理此类敏感材料的财务风险极高，以至于资源往往从创新和采购转移到风险管理。产品的价值更凸显了这种经济负担的沉重。 2024 年医疗保健分销联盟 (HDA) 的一份报告估计，低温运输产品的每日成本是标准非温控药品的 22 倍。如此巨大的成本差异凸显了低温运输故障带来的严重财务损失，使得各机构在扩大库存和限制这些关键生物工具的市场进入方面格外谨慎。

市场趋势

由于治疗研究中对精准基因操作的需求日益增长，开发高性能的CRISPR优化细胞株係正迅速成为关键趋势。製造商正在开发专门的细菌菌株，以稳定大型重复质体有效载荷并降低重组率，这对于可靠的CRISPR-Cas9加工至关重要。产品开发的这项进展直接加速了基因编辑技术从实验室发现到临床应用的转化。为了支持这项商业性进程，Vertex Pharmaceuticals于2023年12月宣布，美国FDA核准了第一个基于CRISPR的基因编辑疗法CASGEVY，这是一个具有里程碑意义的事件，标誌着基因组医学对先进试剂的依赖性日益增强。

同时，与合成生物学相契合的晶圆代工厂工作流程的快速发展，正推动着向自动化友善、高通量活性细胞形式的转变。实验室越来越多地使用自动化液体处理系统，这些系统需要将包装好的细胞置于384孔或96孔盘中进行大规模DNA组装技术，例如Gibson组装和Golden Gate分析。确保大规模实验批次转化效率一致的试剂对于生物学的产业化至关重要。大量的资本投资为这项业务扩张提供了支持。 SynBioBeta预测，到2023年，合成生物学Start-Ups将筹集69亿美元的投资资金，用于支持高度依赖这些专业生物工具的自动化基础设施的发展。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球胜任细胞市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（化学胜任细胞、电胜任细胞）
  • 依应用领域（蛋白质表现、克隆、生物技术、其他应用）
  • 依最终用户（製药/生技公司、学术研究机构、受託研究机构(CRO) 等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美胜任细胞市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲胜任细胞市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胜任细胞市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲胜任细胞市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲胜任细胞市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球胜任细胞市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio Inc.
• New England Biolabs Inc.
• Bio-Rad Laboratories, Inc.
• Transgen Biotech Co., LTD
• Agilent Technologies, Inc.
• Illumina, Inc.
• OriGene Technologies, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Competent Cells Market is projected to expand from USD 2.15 Billion in 2025 to USD 3.88 Billion by 2031, reflecting a CAGR of 10.34%. This market consists of bacterial cells that have been physically or chemically modified to accept foreign genetic material, acting as essential tools for recombinant protein expression and molecular cloning. The sector's growth is largely driven by rising demand for biologic therapeutics and the broadening application of genetic engineering within both industrial and academic landscapes. Furthermore, strong research initiatives within pharmaceutical pipelines support this expansion, as these reagents are crucial for library generation and DNA amplification. According to the International Federation of Pharmaceutical Manufacturers and Associations, the global pharmaceutical pipeline included over 12,700 medicines across various developmental stages in 2024.

Despite this robust growth outlook, the market encounters significant obstacles regarding the rigorous cold chain logistics needed to preserve cell viability. Because competent cells are extremely susceptible to temperature changes, they require continuous ultra-low temperature storage throughout handling and transport. Any fluctuation in these specific environmental conditions can severely diminish transformation efficiency, resulting in experimental failures and escalating operational expenses for commercial laboratories and research institutions.

Market Driver

A primary catalyst for the Global Competent Cells Market is the escalating demand for the production of biologics and recombinant proteins. As biopharmaceutical organizations transition their focus from small-molecule drugs to large-molecule therapeutics, such as recombinant vaccines and monoclonal antibodies, the dependency on high-efficiency competent cells for protein expression and plasmid cloning has deepened. These cells act as essential components for amplifying the genetic material needed for downstream biologic manufacturing, making their usage integral to the success of drug development efforts. According to the U.S. Food and Drug Administration, this surge in activity is evident, as the agency approved 55 novel therapeutics in 2023, including 17 new biological products as of January 2024.

Market growth is further energized by increasing private and government investments in life science research, which supply the necessary capital for advanced workflows and reagent procurement. Strong funding landscapes enable commercial and academic laboratories to secure reliable supplies of high-quality competent cells, which are vital for accelerating project timelines and minimizing experimental variability. For example, JLL reported in September 2024 that venture capital investment in the U.S. life sciences sector rose by 34% during the first half of the year, indicating a fresh wave of capital for R&D. Furthermore, public initiatives support this trajectory; the UK Government announced a £520 million Life Sciences Innovative Manufacturing Fund in October 2024 to strengthen domestic manufacturing capacities for essential diagnostics and medicines.

Market Challenge

The strict necessities of cold chain logistics pose a major hurdle to the expansion of the Global Competent Cells Market. Because competent cells are highly vulnerable to temperature variations, they must be kept at ultra-low temperatures to maintain their transformation efficiency. This fragility demands specialized, expensive shipping protocols utilizing liquid nitrogen or dry ice. The intricacy of these logistical requirements establishes a formidable barrier to entry and growth, as even slight temperature deviations during transport can lead to total cell viability loss, compelling researchers to abandon experiments and absorb substantial financial setbacks.

These operational hazards directly impede market scalability by pressuring the budgets of commercial laboratories and research institutions. The financial risks involved in handling such sensitive materials are extraordinarily high, often shifting resources from innovation and procurement toward risk management. The magnitude of this economic strain is highlighted by the value of the products; according to the Healthcare Distribution Alliance in 2024, the daily dose of a cold chain product was estimated to cost 22 times more than a standard non-temperature-controlled pharmaceutical. This significant cost gap emphasizes the severe financial liability linked to cold chain failures, prompting organizations to exercise caution in expanding inventory and restricting the broader market accessibility of these critical biological tools.

Market Trends

The creation of competent cell strains optimized for CRISPR is rapidly becoming a significant trend, propelled by the requirement for exact genetic manipulation in therapeutic studies. Manufacturers are developing specialized bacterial strains designed to stabilize large, repetitive plasmid payloads and lower recombination rates, which are crucial for reliable CRISPR-Cas9 processes. This product advancement is directly hastening the transition of gene-editing technologies from laboratory discovery to clinical use. Validating this commercial progress, Vertex Pharmaceuticals reported in December 2023 that the U.S. FDA approved the first CRISPR-based gene-editing therapy, CASGEVY, a historic milestone that highlights the increasing dependence on advanced reagents for genomic medicine.

Simultaneously, the growth of biofoundry workflows aligned with synthetic biology is driving a transition toward automation-compatible, high-throughput competent cell formats. Laboratories are increasingly utilizing automated liquid handling systems to perform large-scale DNA assembly techniques, such as Gibson Assembly and Golden Gate, requiring cells packaged in 384-well or 96-well plate configurations. This industrialization of biology necessitates reagents that guarantee uniform transformation efficiencies across high-volume experimental batches. This operational expansion is backed by significant capital investment; according to SynBioBeta's May 2024 report, synthetic biology startups secured $6.9 billion in investment capital in 2023, funding the growth of automated infrastructure that relies heavily on these specialized biological tools.

Key Market Players

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Promega Corporation
• Takara Bio Inc.
• New England Biolabs Inc.
• Bio-Rad Laboratories, Inc.
• Transgen Biotech Co., LTD
• Agilent Technologies, Inc.
• Illumina, Inc.
• OriGene Technologies, Inc

Report Scope

In this report, the Global Competent Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Competent Cells Market, By Type

• Chemically Competent Cell
• Electrocompetent Cells

Competent Cells Market, By Application

• Protein Expression
• Cloning
• Biotechnology
• Other Applications

Competent Cells Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations (CROs)
• others

Competent Cells Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Competent Cells Market.

Available Customizations:

Global Competent Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Competent Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chemically Competent Cell, Electrocompetent Cells)
  • 5.2.2. By Application (Protein Expression, Cloning, Biotechnology, Other Applications)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs), others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Competent Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Competent Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Competent Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Competent Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Competent Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Competent Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Competent Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Competent Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Competent Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Competent Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Competent Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Competent Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Competent Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Competent Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Competent Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Competent Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Competent Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Competent Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Competent Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Competent Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Competent Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Competent Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Competent Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Competent Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Competent Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Promega Corporation
• 15.4. Takara Bio Inc.
• 15.5. New England Biolabs Inc.
• 15.6. Bio-Rad Laboratories, Inc.
• 15.7. Transgen Biotech Co., LTD
• 15.8. Agilent Technologies, Inc.
• 15.9. Illumina, Inc.
• 15.10. OriGene Technologies, Inc

16. Strategic Recommendations

17. About Us & Disclaimer